CREDENCE trial offers new hope to people at risk for kidney failure due to Type 2 diabetes
The first potential new treatment in decades for diabetic kidney disease was revealed in clinical trial results published this month in the New England Journal of Medicine.
Diabetes is the leading cause of kidney failure, and people with diabetes have long been advised to keep their diabetes under control to protect against kidney failure and other serious complications.
Clinical trial results from the CREDENCE clinical trial offered extremely promising news for people who have diabetic kidney disease. The study found that diabetes drug canagliflozin (brand name Invokana®) protects kidney function in people with type 2 diabetes and mild to moderate CKD. Compared with people taking a placebo, patients taking Invokana were 30 percent less likely to progress to kidney failure or to die from either kidney failure or cardiovascular disease.
The kidney community has long awaited new research breakthroughs to help people avoid kidney failure, which is treatable only with dialysis or transplant. News of the CREDENCE trial results garnered great attention because of the significance of the findings.
“Overall, the importance of CREDENCE, a well done and large clinical trial, cannot be overstated,” the New England Journal of Medicine wrote in an editorial.
The manufacturer of Invokana, Janssen Pharmaceutical Companies, has applied to the Food and Drug Administration for a new indication for Invokana so that it can be prescribed for the purposes of reducing the risk of kidney failure and renal or cardiovascular death among people with type 2 diabetes and CKD.